男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Pfizer signs agreement with Hainan pilot zone at CIIE

By Zhou Wenting in Shanghai | chinadaily.com.cn | Updated: 2019-11-07 15:13
Share
Share - WeChat
A logo of Pfizer. [Photo/VCG]

Pfizer, a US-based pharmaceutical company, signed a collaboration agreement with the Boao Lecheng International Medical Tourism Pilot Zone in Hainan province at the ongoing China International Import Expo (CIIE) on Wednesday to accelerate introduction of innovative drugs into the zone and the country.

According to the collaboration framework, three vaccines, including one to treat pneumococcus, and at least seven new medicines, including for treating acute myeloid leukemia and non-small-cell long cancer, which have been approved by the United States Food and Drug Administration and the European Medicines Agency for market launch, will be available in the pilot zone soon.

"It provides us with the opportunity to introduce our latest innovative therapies to the China market within the shortest time by reaching collaboration with the Lecheng pilot zone at the platform of CIIE," said Wu Kun, Pfizer China Biopharma country lead.

"Such practice will enable us to obtain direct clinical responses, which will benefit our better understanding of the detailed needs of the Chinese patients," he said.

The collaboration also involves a joint organization of international academic events and meetings on vaccines and disease prevention. The first meeting is scheduled to be held in the latter half of 2020.

Gu Gang, head of the Boao Lecheng International Medical Tourism Pilot Zone Administration, said: "We welcome global pharmaceutical giants to showcase their first-class drugs and vaccine products in our pilot zone. Such collaboration benefits the high-quality and high-standard development of international medical tourism and high-end medical service within the zone."

Pfizer said China with a large population and a large number of middle class is currently the company's second-largest market in the world, and will continue to be a major market in its global blueprint as medical care and treatment is an important factor amid people's pursuit of a better life.

"We're committed to further development in China by collaborating with the government, hospitals and medical experts to bring more innovative products and solutions into the country to ultimately benefit Chinese patients and better contribute to the Healthy China 2030 Initiative," Wu said.

He praised CIIE, a China-invented global trade and communication platform, for bringing opportunities for business collaboration and showcasing enterprises' science and technology-driven novel products to both professional industry buyers and the public.

"We sincerely hope that we'll continue to participate in exhibition platforms, such as CIIE, in the coming years to better show our commitment to the China market," Wu said.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 类乌齐县| 盐池县| 祁东县| 义乌市| 沧州市| 泰来县| 洪雅县| 大连市| 墨江| 沈丘县| 桐乡市| 库伦旗| 宾阳县| 汉沽区| 疏勒县| 海南省| 海门市| 长葛市| 达孜县| 海南省| 云安县| 梨树县| 肥东县| 赤壁市| 屯门区| 龙游县| 满洲里市| 理塘县| 子洲县| 平谷区| 佛学| 元阳县| 商丘市| 临夏市| 临安市| 黄石市| 岱山县| 江安县| 玉门市| 芦溪县| 柳林县|